DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Objective. Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM). This study aims to review the outcomes of these existing studies and to discuss the therapeutic effects of DPP-4 inhibitors on T1DM. Metho...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2018/5308582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561111611736064 |
|---|---|
| author | Qixian Wang Min Long Hua Qu Rufei Shen Rui Zhang Jing Xu Xin Xiong Hui Wang Hongting Zheng |
| author_facet | Qixian Wang Min Long Hua Qu Rufei Shen Rui Zhang Jing Xu Xin Xiong Hui Wang Hongting Zheng |
| author_sort | Qixian Wang |
| collection | DOAJ |
| description | Objective. Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM). This study aims to review the outcomes of these existing studies and to discuss the therapeutic effects of DPP-4 inhibitors on T1DM. Methods. We thoroughly searched the Medline, Embase, PubMed, and Cochrane Library databases and ClinicalTrials.gov for studies concerning the use of DPP-4 inhibitors in patients with T1DM. Results. In preclinical trials, DPP-4 inhibitors improved the pathogenesis of T1DM. However, only a portion of the studies showed potential efficacy regarding clinical glycemic control and other clinical parameters. From this meta-analysis, pooled data from 5 randomized controlled trials revealed that the additional use of DPP-4 inhibitors resulted in a greater decrease in glycated hemoglobin A1c (HbA1c) levels (0.07%, 95% CI (−0.37%–0.23%)) than insulin monotherapy, although the decrease was not significant. A small decrease in postprandial glucose or insulin consumption was confirmed. Conclusion. Although DPP-4 inhibitors may be beneficial for T1DM, existing studies do not strongly support these positive effects in clinical practice. Further optimized clinical trials are needed. |
| format | Article |
| id | doaj-art-b9cf24f015514c578c8ddb85eb540590 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-b9cf24f015514c578c8ddb85eb5405902025-02-03T01:26:00ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/53085825308582DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-AnalysisQixian Wang0Min Long1Hua Qu2Rufei Shen3Rui Zhang4Jing Xu5Xin Xiong6Hui Wang7Hongting Zheng8Department of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaDepartment of Endocrinology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, ChinaObjective. Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM). This study aims to review the outcomes of these existing studies and to discuss the therapeutic effects of DPP-4 inhibitors on T1DM. Methods. We thoroughly searched the Medline, Embase, PubMed, and Cochrane Library databases and ClinicalTrials.gov for studies concerning the use of DPP-4 inhibitors in patients with T1DM. Results. In preclinical trials, DPP-4 inhibitors improved the pathogenesis of T1DM. However, only a portion of the studies showed potential efficacy regarding clinical glycemic control and other clinical parameters. From this meta-analysis, pooled data from 5 randomized controlled trials revealed that the additional use of DPP-4 inhibitors resulted in a greater decrease in glycated hemoglobin A1c (HbA1c) levels (0.07%, 95% CI (−0.37%–0.23%)) than insulin monotherapy, although the decrease was not significant. A small decrease in postprandial glucose or insulin consumption was confirmed. Conclusion. Although DPP-4 inhibitors may be beneficial for T1DM, existing studies do not strongly support these positive effects in clinical practice. Further optimized clinical trials are needed.http://dx.doi.org/10.1155/2018/5308582 |
| spellingShingle | Qixian Wang Min Long Hua Qu Rufei Shen Rui Zhang Jing Xu Xin Xiong Hui Wang Hongting Zheng DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis Journal of Diabetes Research |
| title | DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
| title_full | DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
| title_fullStr | DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
| title_short | DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
| title_sort | dpp 4 inhibitors as treatments for type 1 diabetes mellitus a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2018/5308582 |
| work_keys_str_mv | AT qixianwang dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT minlong dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT huaqu dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT rufeishen dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT ruizhang dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT jingxu dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT xinxiong dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT huiwang dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis AT hongtingzheng dpp4inhibitorsastreatmentsfortype1diabetesmellitusasystematicreviewandmetaanalysis |